MapLight Therapeutics EBITDA TCAC 5A

Que fait MapLight Therapeutics ? MapLight Therapeutics Inc, a clinical-stage biopharmaceutical company based in Redwood City, California, is focused on developing novel therapeutics for brain disorders. The company, which has 133 employees, is preparing for an IPO scheduled for October 27, 2025. MapLight is dedicated to improving the lives of patients with debilitating central nervous system disorders. Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC). The company is initially developing this candidate for the treatment of schizophrenia and Alzheimer’s disease psychosis. ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the central nervous system to drive efficacy while synchronizing the pharmacokinetics of the agonist and antagonist components to reduce peripheral cholinergic side effects. The company’s second product candidate, ML-004, is a 5-HT1B/1D agonist being developed for social communication deficits and/or irritability in autism spectrum disorder. MapLight is also advancing two preclinical programs, ML-021 and ML-009. The company’s website is https://maplightrx.com/. MapLight Therapeutics est l'une des entreprises les plus populaires sur Eulerpool.